AbbVie has announced that key data regarding Humira (adalimumab) will be presented at the Annual European Congress of Rheumatology (EULAR 2016) June 8-11 in London, England.
The data includes investigational research along with real-world evidence to add to the body of evidence supporting the safety and efficacy of adalimumab, an anti-TNF therapy — as well as AbbVie’s continued efforts to develop therapies for autoimmune diseases such as rheumatoid arthritis.
“At EULAR 2016, AbbVie is presenting scientific research on adalimumab across autoimmune diseases, including new areas like non-infectious uveitis, where there is an unmet need for patients,” said Dominik Hochli, AbbVie’s vice president of Global Medical Affairs, in a press release. “Building on more than a decade of experience in rheumatology, we are focused on expanding treatment options with new therapies to further improve patient care within the rheumatology community across the globe.”
Humira first received FDA approval 13 years ago. Now the therapy, approved in over 90 countries, is used to treat more than 989,000 patients worldwide.
Humira is indicated for the treatment of:
- Moderate-to-severe rheumatoid arthritis (RA);
- Severe active progressive RA not previously treated with methotrexate;
- Active polyarticular juvenile idiopathic arthritis in patients from the age of 2 years;
- Active enthesitis-related arthritis in patients age 6 and older;
- Severe active ankylosing spondylitis (AS);
- Severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI;
- Active and progressive psoriatic arthritis;
- Others like plaque psoriasis or Crohn’s disease.
In addition to the Humira findings, AbbVie will also present research on investigational medicines that are taking several scientific approaches and testing novel solutions to help improve patient care for a series of autoimmune diseases. These presentations will include data from the new ongoing Phase 2 study on ABT-494 – an investigational, once-daily, oral selective JAK1 inhibitor for the treatment of RA.
To see a full list of the 26 AbbVie’s abstracts to be presented at the Congress, read the original press release here.